bluuebunny/crossref_metadata_2025 huggingface dataset:
Figure S1, Figure S2, Figure S3, Table S1 from Antitumor Effect of the Atypical Retinoid ST1926 in Acute Myeloid Leukemia and Nanoparticle Formulation Prolongs Lifespan and Reduces Tumor Burden of Xenograft Mice
Authors: El-Houjeiri Leeanna , Saad Walid , Hayar Berthe , Aouad Patrick , Tawil Nadim , Abdel-Samad Rana , Hleihel Rita , Hamie Maguy , Mancinelli Angelo , Pisano Claudio , El Hajj Hiba , Darwiche Nadine
Published: April 2023

Supplementary Figure S1. Effect of ST1926 on the viability of AML cells; Supplementary Figure S2. Effect of ST1926 on the viability of normal human stem cells; Supplementary Figure S3. Representative histogram analysis of the effects of ST1926 on the cell cycle distribution of AML cells; Supplementary Table 1: Peritoneal volumes (cm3) of treated (n=5 for each group) versus control mice (n=5 for each group) determined at 24-days post-treatment
Supplemental Figure S3 from Penfluridol Represses Integrin Expression in Breast Cancer through Induction of Reactive Oxygen Species and Downregulation of Sp Transcription Factors
Authors: Hedrick Erik , Li Xi , Safe Stephen
Published: April 2023

Supplemental Figure S3. siZBTB10 knockdown rescues cells from penfluridol. Cells were treated with penfluridol or transfected with siZBTB10 or control oligonucleotide alone or in combination (A, B), and whole cell lysates were analyzed by western blots.
Supplemental Figure S2 from Penfluridol Represses Integrin Expression in Breast Cancer through Induction of Reactive Oxygen Species and Downregulation of Sp Transcription Factors
Authors: Hedrick Erik , Li Xi , Safe Stephen
Published: April 2023

Supplemental Figure S2. Myc expression rescues cells from penfluridol. Cells were treated with penfluridol or cMyc expression plasmid (pCDH-cMyc) or empty vector alone or in combination (A, B), and whole cell lysates were analyzed by western blots.
Supplementary Figure 2 from SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression
Authors: Black Jonathan , Menderes Gulden , Bellone Stefania , Schwab Carlton L. , Bonazzoli Elena , Ferrari Francesca , Predolini Federica , De Haydu Christopher , Cocco Emiliano , Buza Natalia , Hui Pei , Wong Serena , Lopez Salvatore , Ratner Elena , Silasi Dan-Arin , Azodi Masoud , Litkouhi Babak , Schwartz Peter E. , Goedings Peter , Beusker Patrick H. , van der Lee Miranda M.C. , Timmers C. Marco , Dokter Wim H.A. , Santin Alessandro D.
Published: April 2023

Exposure of all nine cell lines to scalar concentrations of ADC for a total of 6 days. IC50 dose response curves of SYD985, T-DM1 and ADC isotype control in all 9 primary USC cell lines with differential HER2 expression tested in vitro (i.e., three with HER2 3+ expression, two with HER2 2+ expression and four with HER2 1+ expression) at 6 days (ie, 144 hrs).
Supplementary Figure 1 from SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression
Authors: Black Jonathan , Menderes Gulden , Bellone Stefania , Schwab Carlton L. , Bonazzoli Elena , Ferrari Francesca , Predolini Federica , De Haydu Christopher , Cocco Emiliano , Buza Natalia , Hui Pei , Wong Serena , Lopez Salvatore , Ratner Elena , Silasi Dan-Arin , Azodi Masoud , Litkouhi Babak , Schwartz Peter E. , Goedings Peter , Beusker Patrick H. , van der Lee Miranda M.C. , Timmers C. Marco , Dokter Wim H.A. , Santin Alessandro D.
Published: April 2023

Exposure of all nine cell lines to scalar concentrations of ADC for a total of 3 days. IC50 dose response curves of SYD985, T-DM1 and ADC isotype control in all 9 primary USC cell lines with differential HER2 expression tested in vitro (i.e., three with HER2 3+ expression, two with HER2 2+ expression and four with HER2 1+ expression) at 3 days.
Suppl. Table 1 from Upregulation of AKT3 Confers Resistance to the AKT Inhibitor MK2206 in Breast Cancer
Authors: Stottrup Casey , Tsang Tiffany , Chin Y. Rebecca
Published: April 2023

Table showing differentially expressed genes in T47D MK2206-resistant cells.
Suppl. Figure 3 from Upregulation of AKT3 Confers Resistance to the AKT Inhibitor MK2206 in Breast Cancer
Authors: Stottrup Casey , Tsang Tiffany , Chin Y. Rebecca
Published: April 2023

Knockdown of AKT3 sensitizes AKTi-resistant breast tumor cells to MK2206.
Supplementary Table 9 from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib
Authors: Miller Rowan E. , Brough Rachel , Bajrami Ilirjana , Williamson Chris T. , McDade Simon , Campbell James , Kigozi Asha , Rafiq Rumana , Pemberton Helen , Natrajan Rachel , Joel Josephine , Astley Holly , Mahoney Claire , Moore Jonathan D. , Torrance Chris , Gordan John D. , Webber James T. , Levin Rebecca S. , Shokat Kevan M. , Bandyopadhyay Sourav , Lord Christopher J. , Ashworth Alan
Published: April 2023

MS Stats output from dasatinib bead proteomics, see also Figure 3
Supplementary figure s5 from Antagonizing the Hedgehog Pathway with Vismodegib Impairs Malignant Pleural Mesothelioma Growth In Vivo by Affecting Stroma
Authors: Meerang Mayura , Bérard Karima , Felley-Bosco Emanuela , Lauk Olivia , Vrugt Bart , Boss Andreas , Kenkel David , Broggini-Tenzer Angela , Stahel Rolf A. , Arni Stephan , Weder Walter , Opitz Isabelle
Published: April 2023

Vismodegib does not interfere with in vivo Bli measurement
Supplementary Table 6 from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib
Authors: Miller Rowan E. , Brough Rachel , Bajrami Ilirjana , Williamson Chris T. , McDade Simon , Campbell James , Kigozi Asha , Rafiq Rumana , Pemberton Helen , Natrajan Rachel , Joel Josephine , Astley Holly , Mahoney Claire , Moore Jonathan D. , Torrance Chris , Gordan John D. , Webber James T. , Levin Rebecca S. , Shokat Kevan M. , Bandyopadhyay Sourav , Lord Christopher J. , Ashworth Alan
Published: April 2023

Pearson's correlation and Z prime values for OCCC panel demonstrating robust reproducibility and dynamic range from the high-throughput drug screen
Supplementary figure s4 from Antagonizing the Hedgehog Pathway with Vismodegib Impairs Malignant Pleural Mesothelioma Growth In Vivo by Affecting Stroma
Authors: Meerang Mayura , Bérard Karima , Felley-Bosco Emanuela , Lauk Olivia , Vrugt Bart , Boss Andreas , Kenkel David , Broggini-Tenzer Angela , Stahel Rolf A. , Arni Stephan , Weder Walter , Opitz Isabelle
Published: April 2023

Supernatant from rat and human MPM cells could stimulate Gli1 Ptch1 and Fn1 expression of NIH3T3 cells
Supplementary figure s3 from Antagonizing the Hedgehog Pathway with Vismodegib Impairs Malignant Pleural Mesothelioma Growth In Vivo by Affecting Stroma
Authors: Meerang Mayura , Bérard Karima , Felley-Bosco Emanuela , Lauk Olivia , Vrugt Bart , Boss Andreas , Kenkel David , Broggini-Tenzer Angela , Stahel Rolf A. , Arni Stephan , Weder Walter , Opitz Isabelle
Published: April 2023

Reduced fibronectin protein levels in tumor treated with vismodegib
Supplementary Video S3. Interphase microtubule dynamics in HeLa-EB1-GFP treated with DMSO. from 6α-Acetoxyanopterine: A Novel Structure Class of Mitotic Inhibitor Disrupting Microtubule Dynamics in Prostate Cancer Cells
Authors: Levrier Claire , Sadowski Martin C. , Rockstroh Anja , Gabrielli Brian , Kavallaris Maria , Lehman Melanie , Davis Rohan A. , Nelson Colleen C.
Published: April 2023

EB1-GFP was imaged by spinning disk microscopy (1 image/s for 1 min). EB1 comets were clearly discernible and followed regular trajectories. Scale bar=10 Âµm.
Supplementary Video S1.Time-lapse microscopy of HeLa-H2B-GFP cells treated with DMSO, vinblastine (20 nM) or 6-AA (0.62 nM). from 6α-Acetoxyanopterine: A Novel Structure Class of Mitotic Inhibitor Disrupting Microtubule Dynamics in Prostate Cancer Cells
Authors: Levrier Claire , Sadowski Martin C. , Rockstroh Anja , Gabrielli Brian , Kavallaris Maria , Lehman Melanie , Davis Rohan A. , Nelson Colleen C.
Published: April 2023

HeLa-H2B-GFP cells were imaged using an Olympus IX81 (1 image/5 min for 24 h). Top panels: brightfield, bottom panels: H2B-GFP. DMSO-treated cells normally progressed through mitosis, which was delayed with vinblastine (20 nM) and low dose of 6-AA (0.62 nM). Both compounds induced asymmetric division. In addition, vinblastine caused cell death. Scale bar=20 Âµm. nM).
Figure S6 from Macrophage Susceptibility to Emactuzumab (RG7155) Treatment
Authors: Pradel Leon P. , Ooi Chia-Huey , Romagnoli Solange , Cannarile Michael A. , Sade Hadassah , Rüttinger Dominik , Ries Carola H.
Published: April 2023

RNA expression of MÏ† and dendritic cell markers in different immune cell populations and MÏ† subsets as well as patient tumor and RG7155 treated cynomolgus tissues
Supplementary Table S2: Tissue Information. from Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8+/PDL1+ Immune Infiltration in Inflammatory Breast Cancer Tumors
Authors: Hamm Christopher A. , Moran Diarmuid , Rao Kakuturu , Trusk Patricia B. , Pry Karen , Sausen Mark , Jones Siân , Velculescu Victor E. , Cristofanilli Massimo , Bacus Sarah
Published: April 2023

Sample ID and Tissue Information.
Supplementary Tables S1, S3-S7, Supplementary Material and Methods, and Supplementary Figure Legends from Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma
Authors: Weeden Clare E. , Holik Aliaksei Z. , Young Richard J. , Ma Stephen B. , Garnier Jean-Marc , Fox Stephen B. , Antippa Phillip , Irving Louis B. , Steinfort Daniel P. , Wright Gavin M. , Russell Prudence A. , Ritchie Matthew E. , Burns Christopher J. , Solomon Benjamin , Asselin-Labat Marie-Liesse
Published: April 2023

Supplementary Table 1. Engraftment rates of lung cancer patient-derived xenografts vary according to histology and specimen type; Supplementary Table 3. TP53 mutations in primary lung cancer and corresponding PDX, as detected by exome sequencing; Supplementary Table 4. FGFR1 FISH scores are conserved for successive passages of squamous cell carcinoma PDXs 792, 406, 788, and 926; Supplementary Table 5. FGFR1 gene amplification does not always correlate with FGFR1 RNA expression in a tissue microarray patient cohort; Supplementary Table 6. FGFR1 gene amplification does not always correlate with FGFR1 RNA expression in squamous cell carcinoma patients from a tissue microarray cohort; Supplementary Table 7. FGFR1 gene amplification does not always correlate with RNA expression in a squamous cell carcinoma PDX cohort; Supplementary Material and Methods, and Supplementary Figure Legends
Supplementary Figures 1 and 2 from Elevated Translation Initiation Factor eIF4E Is an Attractive Therapeutic Target in Multiple Myeloma
Authors: Li Shirong , Fu Jing , Lu Caisheng , Mapara Markus Y. , Raza Shahzad , Hengst Ulrich , Lentzsch Suzanne
Published: April 2023

Supplementary Figures 1. Analysis of eIF4E protein levels by western blotting of whole cell extracts from primary stromal cells, CD138- cells, primary myeloma cells (CD138+) and normal plasma cells. Supplementary Figures 2. CT shRNA, eIF4E shRNA, PCDH-GFP or PCDH-eIF4E U266 cells were analyzed by Annexin V binding/ PI staining for apoptotic cells.
Figure S1-S6 from Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma
Authors: Weeden Clare E. , Holik Aliaksei Z. , Young Richard J. , Ma Stephen B. , Garnier Jean-Marc , Fox Stephen B. , Antippa Phillip , Irving Louis B. , Steinfort Daniel P. , Wright Gavin M. , Russell Prudence A. , Ritchie Matthew E. , Burns Christopher J. , Solomon Benjamin , Asselin-Labat Marie-Liesse
Published: April 2023

Supplementary Fig. S1. Generation of patient-derived xenografts from surgery and biopsy specimens of non small cell lung cancer Supplementary Fig. S2. Squamous cell carcinoma patient-derived xenografts recapitulate the genomic phenotype of patients'' tumors Supplementary Fig. S3. Analysis of biomarkers of response to FGFR inhibition Supplementary Fig. S4. High FGFR1 RNA expression does not predict patient outcome Supplementary Fig. S5. PIK3CA amplification does not predict response to PI3K inhibitors Supplementary Fig. S6. FGFR targeted therapy in FGFR inhibitor resistant tumors does not increase cisplatin sensitivity
Supplementary Figure S1 from Modeling Therapy Response and Spatial Tissue Distribution of Erlotinib in Pancreatic Cancer
Authors: Grüner Barbara M. , Winkelmann Isabel , Feuchtinger Annette , Sun Na , Balluff Benjamin , Teichmann Nicole , Herner Alexander , Kalideris Evdokia , Steiger Katja , Braren Rickmer , Aichler Michaela , Esposito Irene , Schmid Roland M. , Walch Axel , Siveke Jens T.
Published: April 2023

Supplementary Figure S1 This supplementary figure depicts the ion suppression of erlotinib of different histological compartments of the pancreas and its specific measurement on tissue sections.
Supplementary Table S1 and S2 from The Discovery and Characterization of K-756, a Novel Wnt/β-Catenin Pathway Inhibitor Targeting Tankyrase
Authors: Okada-Iwasaki Ryoko , Takahashi Yuichi , Watanabe Yasuo , Ishida Hiroshi , Saito Jun-ichi , Nakai Ryuichiro , Asai Akira
Published: April 2023

Supplementary Table S1: The correlation coefficients of the gene expression profiles between CTNNB1 siRNAs and XAV939- or K-756-treated cells. Supplementary Table S2: The reporter inhibitory activity and cell growth inhibitory activity of K-756, XAV939 and IWR-1.
Supplemental Figure 5: UAB30 decreased tumor growth in SK-NEP-1 xenografts. from Preclinical Evaluation of UAB30 in Pediatric Renal and Hepatic Malignancies
Authors: Waters Alicia M. , Stewart Jerry E. , Atigadda Venkatram R. , Mroczek-Musulman Elizabeth , Muccio Donald D. , Grubbs Clinton J. , Beierle Elizabeth A.
Published: April 2023

In the SK-NEP-1 in vivo experiments, the animals fed UAB30 chow, although healthy throughout the experiment, gained weight at a slower rate than animals fed vehicle-treated chow. To demonstrate that the smaller size did not affect the tumor volumes, we calculated a tumor weight to animal weight ratio to correct for the smaller size of the UAB30 treated animals. There was a significant decrease between the tumor : animal weight ratio between animals treated with UAB30 compared to vehicle, demonstrating that decreased animal weight was not responsible for decreased tumor growth.
Supplementary Figure 8 from 3D Growth of Cancer Cells Elicits Sensitivity to Kinase Inhibitors but Not Lipid Metabolism Modifiers
Authors: Jones Dylan T. , Valli Alessandro , Haider Syed , Zhang Qifeng , Smethurst Elizabeth A. , Schug Zachary T. , Peck Barrie , Aboagye Eric O. , Critchlow Susan E. , Schulze Almut , Gottlieb Eyal , Wakelam Michael J.O. , Harris Adrian L.
Published: April 2023

Analysis of saturated, mono-unsaturated and poly-unsaturated phospholipids in MDA-MB-468 and PC3 spheroids. Levels of PC, PE, PI, PS, and SM in MDA-MB-468 and PC3 spheroids treated with inhibitors against metabolic enzymes PDHK, ACC, FASN and DGAT, and signalling enzymes PI3K, Akt and mTOR at two different concentrations. Data were converted to log2 scale for each replicate. Abundance of saturated, monounsaturated and polyunsaturated members within each family were then compared using one-way ANOVA, followed by Tukey Post-hoc test for pair-wise comparison (* p<0.05).
Supplementary Figure 5 from 3D Growth of Cancer Cells Elicits Sensitivity to Kinase Inhibitors but Not Lipid Metabolism Modifiers
Authors: Jones Dylan T. , Valli Alessandro , Haider Syed , Zhang Qifeng , Smethurst Elizabeth A. , Schug Zachary T. , Peck Barrie , Aboagye Eric O. , Critchlow Susan E. , Schulze Almut , Gottlieb Eyal , Wakelam Michael J.O. , Harris Adrian L.
Published: April 2023

Clustered heat map analysis of lipids in MDA-MB-468 and PC3 spheroids treated for 4 days with A. FASN and B. DGAT inhibitor at different concentrations. All Lipids were compared against DMSO control. Side covariates indicate lipid families, and lipids within each family are sorted by name.
Supplementary Figure 3 from 3D Growth of Cancer Cells Elicits Sensitivity to Kinase Inhibitors but Not Lipid Metabolism Modifiers
Authors: Jones Dylan T. , Valli Alessandro , Haider Syed , Zhang Qifeng , Smethurst Elizabeth A. , Schug Zachary T. , Peck Barrie , Aboagye Eric O. , Critchlow Susan E. , Schulze Almut , Gottlieb Eyal , Wakelam Michael J.O. , Harris Adrian L.
Published: April 2023

GI50 calculation of spheroids treated with inhibitors. (A) MDA-MB-468 on day 8 and (B) PC3 spheroids on day 12 treated with inhibitors against metabolic enzymes PDHK, ACC, FASN and DGAT, and signalling enzymes PI3K, Akt and mTOR. Between 5 and 15 spheroids were measured per condition, errors bars represent standard deviation and GI50 values were calculated using Graph Prism.
Supplementary Figure S5 from Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib
Authors: Eigenmann Miro J. , Frances Nicolas , Hoffmann Gerhard , Lavé Thierry , Walz Antje-Christine
Published: April 2023

Shows the goodness of fit plots when fitting a 1-compartmental model to the long term plasma PK data.
Supplementary Figure S4 from Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib
Authors: Eigenmann Miro J. , Frances Nicolas , Hoffmann Gerhard , Lavé Thierry , Walz Antje-Christine
Published: April 2023

Shows the total-Erk time course in patient derived A677 tumors after single dose application of erlotinib or gefitinib respectively.
Table S3 from A New Class of Antibody–Drug Conjugates with Potent DNA Alkylating Activity
Authors: Miller Michael L. , Fishkin Nathan E. , Li Wei , Whiteman Kathleen R. , Kovtun Yelena , Reid Emily E. , Archer Katie E. , Maloney Erin K. , Audette Charlene A. , Mayo Michele F. , Wilhelm Alan , Modafferi Holly A. , Singh Rajeeva , Pinkas Jan , Goldmacher Victor , Lambert John M. , Chari Ravi V.J.
Published: April 2023

Extent of DNA adduct formation in EOL-1 (AML cells) exposed to the IGN diimine 7 or the monoimine 8 after a 5 h or 20 h exposure to the compounds
Supplementary Figure S2 from Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib
Authors: Eigenmann Miro J. , Frances Nicolas , Hoffmann Gerhard , Lavé Thierry , Walz Antje-Christine
Published: April 2023

Graphs displaying plasma PK profile of the long term and short term experiments for erlotinib and gefitinib.
Supplementary Figure S1 from Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib
Authors: Eigenmann Miro J. , Frances Nicolas , Hoffmann Gerhard , Lavé Thierry , Walz Antje-Christine
Published: April 2023

Graph describing the impact of tumor volume on the derivation of the concentration to achieve tumor stasis when considering a non-linear tumor growth behavior.
Supplementary Methods from A New Class of Antibody–Drug Conjugates with Potent DNA Alkylating Activity
Authors: Miller Michael L. , Fishkin Nathan E. , Li Wei , Whiteman Kathleen R. , Kovtun Yelena , Reid Emily E. , Archer Katie E. , Maloney Erin K. , Audette Charlene A. , Mayo Michele F. , Wilhelm Alan , Modafferi Holly A. , Singh Rajeeva , Pinkas Jan , Goldmacher Victor , Lambert John M. , Chari Ravi V.J.
Published: April 2023

Synthesis of IGNs
Supplementary Figures S1-S5 from A New Class of Antibody–Drug Conjugates with Potent DNA Alkylating Activity
Authors: Miller Michael L. , Fishkin Nathan E. , Li Wei , Whiteman Kathleen R. , Kovtun Yelena , Reid Emily E. , Archer Katie E. , Maloney Erin K. , Audette Charlene A. , Mayo Michele F. , Wilhelm Alan , Modafferi Holly A. , Singh Rajeeva , Pinkas Jan , Goldmacher Victor , Lambert John M. , Chari Ravi V.J.
Published: April 2023

Figure S1. Comparison of the rate of adduct formation of the indolinobenzodiazepine dimer 6 and the pyrrolobenzodiazepine dimer SJG-136 with dsDNA prepared from annealing of single strand DNA 3'-TATAGATCTATA-5'. Figure S2. A, In vitro potency of anti-EpCAM ADC 1a toward antigen (+) HCT-15 cells without or with addition of blocking antibody. Figure S3. A, Structures of IGNs used in the DNA adduct formation assay. B, Time-dependent reversal of IGN-DNA adducts isolated from EOL-1 cells that had been exposed to the IGN diimine 7 or the monoimine 8, after heating to 90{degree sign} C. C, The ability of IGN 7 (diimine) and 8 (monoimine) to crosslink DNA was tested in an acellular comet assay with nuclear DNA from human normal lymphocytes. Figure S4. In vitro potency of anti-FRα ADC 4a toward antigen (+) KB cells without or with addition of an excess (1 x 10-6 M) blocking antibody. Figure S5. Comparison of the in vitro potency of IGN 9 and its sulfonated version towards the human Burkitt cell line Namalwa.
Supplementary Information from Discovery of a Novel Small-Molecule Inhibitor that Targets PP2A–β-Catenin Signaling and Restricts Tumor Growth and Metastasis
Authors: Maheshwari Shrankhla , Avula Srinivasa R. , Singh Akhilesh , Singh L. Ravithej , Palnati Gopala R. , Arya Rakesh K. , Cheruvu Srikanth H. , Shahi Sudhir , Sharma Tanuj , Meena Sanjeev , Singh Anup K. , Kant Ruchir , Riyazuddin Mohammed , Bora Himangsu K. , Siddiqi Mohammad I. , Gayen Jiaur R. , Sashidhara Koneni V. , Datta Dipak
Published: April 2023

SUPPLEMENTARY FIGURE S1: General information and rationale of synthesis of hybrid molecules of Chalcone and Semicarbazone SUPPLEMENTARY FIGURE S2: Detailed qualitative analysis of compounds of Chalcone and Semicarbazone hybrid series Supplementary Figure S2a: NMR spectra and structure of compounds Supplementary Figure S2b: HPLC chromatogram of compounds Supplementary Figure S2c: Crystal structure of representative CS-24 SUPPLEMENTARY FIGURE S3: Dose dependent cytotoxic potential of CS-11 and parent compound 8e on different breast cell lines SUPPLEMENTARY FIGURE S4: Densitometric quantification and statistical analysis of western blots shown in Figure 2d SUPPLEMENTARY FIGURE S5: Effect of CS-11 on colon cancer cell growth inhibition and breast cancer cell migration Supplementary Figure S5a: IC50 and Dose dependent cytotoxic potential of CS-11 and parent compound 8e on SW620 colon cancer cell line Supplementary Figure S5b: Effect of CS-11 on breast cancer cell migration in in vitro scratch assay SUPPLEMENTARY FIGURE S6: Densitometric quantification and statistical analysis of western blots shown in Figure 5a (S6a) and 5c (S6b) SUPPLEMENTARY FIGURE S7: Densitometric quantification and statistical analysis of western blots shown in Figure 6a SUPPLEMENTARY TABLE S1: Crystal data and structure refinement details for representative compound CS-24 SUPPLEMENTARY TABLE S2: Cytotoxic potential of CS series on different cancer cell lines Supplementary Table S2a: Differential response of Chalcone Semicarbazone hybrids series on different cancer cells Supplementary Table S2b CS-11 induces breast cancer cell selective cytotoxic effects SUPPLEMENTARY METHODS Supplementary Method S1: Detailed procedure of compound synthesis Supplementary Method S2: X-Ray data collection and structure refinement details Supplementary Method S3: Methodology for pharmacokinetic studies
Supplementary Figure 1 from Combining ABCG2 Inhibitors with IMMU-132, an Anti–Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers
Authors: Chang Chien-Hsing , Wang Yang , Zalath Maria , Liu Donglin , Cardillo Thomas M. , Goldenberg David M.
Published: April 2023

Molecular structure of fumitremorgin C
Supplementary Data from Potency-matched Dual Cytokine–Antibody Fusion Proteins for Cancer Therapy
Authors: De Luca Roberto , Soltermann Alex , Pretto Francesca , Pemberton-Ross Catherine , Pellegrini Giovanni , Wulhfard Sarah , Neri Dario
Published: April 2023

Supplementary Figure S1: Amino acid sequence of IL2-F8-TNF; Supplementary Figure S2: murine TNF mutants screening; Supplementary Figure S3: Analysis of toxicity form therapy by observation of changes in the weight of mice; Supplementary Figure S4: Necroscopic analysis of organs after IL2-F8-TNFmut (right panels) treatment compared to PBS. Supplementary Figure S5: Immunofluorescence analysis of tumor infiltrating NK cells; Supplementary Figure S6: human TNF mutants screening; Supplementary Figure S7: Cloning expression and characterisation of fully-human IL2-F8- TNFmut
Supplementary Table from EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E–Mutant NSCLC Cell Lines
Authors: Kim Sung-Moo , Kim Hwan , Jang Kang Won , Kim Min Hwan , Sohn Jinyoung , Yun Mi Ran , Kang Han Na , Kang Chan Woo , Kim Hye Ryun , Lim Sun Min , Moon Yong Wha , Kim Joo Hang , Paik Soonmyung , Cho Byoung Chul
Published: April 2023

Supplementary Table S1. Sequencing primers (Sanger) Supplementary Table S2. siRNA sequences
Supplementary Figure S2. Autocrine HB-EGF-EGFR signaling mediates resistance to GSK2118436 in MV522 and HCC364 cells. from EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E–Mutant NSCLC Cell Lines
Authors: Kim Sung-Moo , Kim Hwan , Jang Kang Won , Kim Min Hwan , Sohn Jinyoung , Yun Mi Ran , Kang Han Na , Kang Chan Woo , Kim Hye Ryun , Lim Sun Min , Moon Yong Wha , Kim Joo Hang , Paik Soonmyung , Cho Byoung Chul
Published: April 2023

A, mRNA expression levels of EGFR ligands in MV522 and GSR cells. B, MV522 and HCC364 cells were treated with 1 µM GSK2118436 in the absence or presence of each ligand. Cellular lysates were probed with the indicated antibodies in western blots.
Figure S2 from Alkylating Agent–Induced NRF2 Blocks Endoplasmic Reticulum Stress–Mediated Apoptosis via Control of Glutathione Pools and Protein Thiol Homeostasis
Authors: Zanotto-Filho Alfeu , Masamsetti V. Pragathi , Loranc Eva , Tonapi Sonal S. , Gorthi Aparna , Bernard Xavier , Gonçalves Rosângela Mayer , Moreira José C.F. , Chen Yidong , Bishop Alexander J.R.
Published: April 2023

Effect of NAC, GSH-ethyl-ester or BSO on glutathione levels; Immunoblots for validation of NRF2-myc and GRP78-pcDNA3 overexpressions; mRNA levels of MRP and MDR gene expressions; Cell-titer Glo assays following inhibitors of MDR and MRP (verapamil and MK517) and thioredoxin reductase (auranofin); Immunoblots to demonstrate the purity of MDA-MB231 cell fractions; Dibromobimane assay showing that 10 mM DTT incubation does not restore Protein-SH levels depleted by MMS.
Supplementary Figure S1. Combination of GSK2118436 and a c-MET inhibitor, SU11274, did not restore sensitivity to GSK2118436. from EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E–Mutant NSCLC Cell Lines
Authors: Kim Sung-Moo , Kim Hwan , Jang Kang Won , Kim Min Hwan , Sohn Jinyoung , Yun Mi Ran , Kang Han Na , Kang Chan Woo , Kim Hye Ryun , Lim Sun Min , Moon Yong Wha , Kim Joo Hang , Paik Soonmyung , Cho Byoung Chul
Published: April 2023

A, Lysates from MV522 cells and GSR cells were evaluated by western blotting to determine total and phosphorylated c-MET levels from the arrays in Fig. 3A. B, MV522 cells and GSR cells were cultured in control (CTL), 0.1 µM GSK2118436 (GSK), or 2 µM SU11274 alone or in combination (GSK + SU). Cell viability was determined using MTT (5 μg/mL) solution by measuring the absorbance at 540 nm in a microplate reader after 72 h for short-term growth inhibition assays. All data are normalized to GSK2118436 or control and are displayed as mean {plus minus} SEM (n = 3, **P < 0.01).
Supplementary Materials and Methods; Supplementary Tables 1-6; and Supplementary Figure Legends from Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity
Authors: Wengner Antje M. , Siemeister Gerhard , Koppitz Marcus , Schulze Volker , Kosemund Dirk , Klar Ulrich , Stoeckigt Detlef , Neuhaus Roland , Lienau Philip , Bader Benjamin , Prechtl Stefan , Raschke Marian , Frisk Anna-Lena , von Ahsen Oliver , Michels Martin , Kreft Bertolt , von Nussbaum Franz , Brands Michael , Mumberg Dominik , Ziegelbauer Karl
Published: April 2023

Additional data showing pharmacological characterization of Mps1 Inhibitors BAY 1161909 and BAY 1217389; Suppl. Table 1: Kinase selectivity profile of BAY 1161909; Suppl. Table 2: Kinase selectivity profile of BAY 1217389; Suppl. Table 3: Kinase selectivity profiles of BAY 1161909 compared to SP600125 and Reversine; Suppl. Table 4: Inhibition of tumor cell proliferation by BAY 1161909 or BAY 1217389; Suppl. Table 5: Summary of in vivo activity of BAY 1161909 in human xenograft tumor models in mice; Suppl. Table 6: Summary of in vivo activity of BAY 1217389 in human xenograft tumor models in mice.
Supplementary Figure S2 from β-Catenin Inhibitor BC2059 Is Efficacious as Monotherapy or in Combination with Proteasome Inhibitor Bortezomib in Multiple Myeloma
Authors: Savvidou Ioanna , Khong Tiffany , Cuddihy Andrew , McLean Catriona , Horrigan Stephen , Spencer Andrew
Published: April 2023

Cytotoxic effect of BC2059 in HMCL at 72h.
Suppl. Figure 2 from Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity
Authors: Wengner Antje M. , Siemeister Gerhard , Koppitz Marcus , Schulze Volker , Kosemund Dirk , Klar Ulrich , Stoeckigt Detlef , Neuhaus Roland , Lienau Philip , Bader Benjamin , Prechtl Stefan , Raschke Marian , Frisk Anna-Lena , von Ahsen Oliver , Michels Martin , Kreft Bertolt , von Nussbaum Franz , Brands Michael , Mumberg Dominik , Ziegelbauer Karl
Published: April 2023

H&E stained A2780cis tumors after treatment with vehicle paclitaxel alone BAY 1161909 alone or in combination with BAY 1161909 and paclitaxel
Supplementary Figure S1 from β-Catenin Inhibitor BC2059 Is Efficacious as Monotherapy or in Combination with Proteasome Inhibitor Bortezomib in Multiple Myeloma
Authors: Savvidou Ioanna , Khong Tiffany , Cuddihy Andrew , McLean Catriona , Horrigan Stephen , Spencer Andrew
Published: April 2023

Chemical structure of beta-catenin antagonist, BC2059.
Supplemental Tables from Selective Glucocorticoid Receptor Modulators (SGRMs) Delay Castrate-Resistant Prostate Cancer Growth
Authors: Kach Jacob , Long Tiha M. , Selman Phillip , Tonsing-Carter Eva Y. , Bacalao Maria A. , Lastra Ricardo R. , de Wet Larischa , Comiskey Shane , Gillard Marc , VanOpstall Calvin , West Diana C. , Chan Wen-Ching , Griend Donald Vander , Conzen Suzanne D. , Szmulewitz Russell Z.
Published: April 2023

Supplemental Tables 1-2
Supplemental Figures from Selective Glucocorticoid Receptor Modulators (SGRMs) Delay Castrate-Resistant Prostate Cancer Growth
Authors: Kach Jacob , Long Tiha M. , Selman Phillip , Tonsing-Carter Eva Y. , Bacalao Maria A. , Lastra Ricardo R. , de Wet Larischa , Comiskey Shane , Gillard Marc , VanOpstall Calvin , West Diana C. , Chan Wen-Ching , Griend Donald Vander , Conzen Suzanne D. , Szmulewitz Russell Z.
Published: April 2023

Supplemental Figures 1-8
Lilienthal N et al., Immunokinase-based B-lymphotoxic delivery of activated DAPK1; Supplements from A Novel Recombinant Anti-CD22 Immunokinase Delivers Proapoptotic Activity of Death-Associated Protein Kinase (DAPK) and Mediates Cytotoxicity in Neoplastic B Cells
Authors: Lilienthal Nils , Lohmann Gregor , Crispatzu Giuliano , Vasyutina Elena , Zittrich Stefan , Mayer Petra , Herling Carmen Diana , Tur Mehmet Kemal , Hallek Michael , Pfitzer Gabriele , Barth Stefan , Herling Marco
Published: April 2023

Table S1: Expression of DAPK1 (a) and surface CD22 (b) in various cell lines; Table S2: Characteristics of CLL patients from whom samples were analyzed including for DAPK1/2 expression and responses to DK1KD-SGIII;Figure S1: Analysis of DAPK expression in B-cells and B-cell lymphomas; Figure S2: Short-term overexpression of DAPK mutants; Figure S3: Variants of the pMS expression vector; Figure S4: Principle of the kinase activity assay; Figure S5: DK1KD-SGIII binding differs between CD22 expressing cell lines; Figure S6: DK1KD-SGIII binds to primary CLL cells in a dose-dependent manner; Figure S7: DK1KD-SGIII, but not DK1KD and SGIII controls, induces profound and specific cell death in CD22(+) cells.
Supplementary Figures 1-6 from CDK4/6 Inhibitors Sensitize Rb-positive Sarcoma Cells to Wee1 Kinase Inhibition through Reversible Cell-Cycle Arrest
Authors: Francis Ashleigh M. , Alexander Angela , Liu Yanna , Vijayaraghavan Smruthi , Low Kwang Hui , Yang Dong , Bui Tuyen , Somaiah Neeta , Ravi Vinod , Keyomarsi Khandan , Hunt Kelly K.
Published: April 2023

Supplemental Figure 1: Schematic of HTSA and dose response curves of doxorubicin and AZD-1775 in different cell lines. Supplemental Figure 2: Cell cycle analysis following palbociclib treatment. Supplemental Figure 3: Schematic of combination index determination and combination index values of different drug combinations. Supplemental Figure 4: Combination treatment efficacy in SK-LMS1 Rb knockdown cells. Supplemental Figure 5: Western blot for apoptosis markers for SK-LMS1 cells treated with palbociclib. Supplemental Figure 6: Mouse weights over course of vehicle, single drugs and combination treatments.
Table S2 from Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation
Authors: Yamaoka Toshimitsu , Ohmori Tohru , Ohba Motoi , Arata Satoru , Kishino Yasunari , Murata Yasunori , Kusumoto Sojiro , Ishida Hiroo , Shirai Takao , Hirose Takashi , Ohnishi Tsukasa , Sasaki Yasutsuna
Published: April 2023

Primer sequences
Supplementary Information from PI3Kγ/δ and NOTCH1 Cross-Regulate Pathways That Define the T-cell Acute Lymphoblastic Leukemia Disease Signature
Authors: Efimenko Evgeni , Davé Utpal P. , Lebedeva Irina V. , Shen Yao , Sanchez-Quintero Maria J. , Diolaiti Daniel , Kung Andrew , Lannutti Brian J. , Chen Jianchung , Realubit Ronald , Niatsetskaya Zoya , Ten Vadim , Karan Charles , Chen Xi , Califano Andrea , Diacovo Thomas G.
Published: April 2023

5 supplementary figures Supplementary figure legends 3 supplementary tables Supplementary methods Supplementary references
Figure S5 from Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation
Authors: Yamaoka Toshimitsu , Ohmori Tohru , Ohba Motoi , Arata Satoru , Kishino Yasunari , Murata Yasunori , Kusumoto Sojiro , Ishida Hiroo , Shirai Takao , Hirose Takashi , Ohnishi Tsukasa , Sasaki Yasutsuna
Published: April 2023

Loss of DUSP4 abundance leads to ERK1/2 phosphorylation as a negative feedback loop.
Supplementary Tables from Gastric Adenocarcinomas Express the Glycosphingolipid Gb3/CD77: Targeting of Gastric Cancer Cells with Shiga Toxin B-Subunit
Authors: Geyer Philipp Emanuel , Maak Matthias , Nitsche Ulrich , Perl Markus , Novotny Alexander , Slotta-Huspenina Julia , Dransart Estelle , Holtorf Anne , Johannes Ludger , Janssen Klaus-Peter
Published: April 2023

Supplementary Tables: I) Gastric Carcinoma Patient Collective and Clinical Data II) Patient collective with clinically manifest gastritis III) Characteristics of cancer cell lines IV) IC50-values for gastric cancer cell lines
Figure S2 from Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation
Authors: Yamaoka Toshimitsu , Ohmori Tohru , Ohba Motoi , Arata Satoru , Kishino Yasunari , Murata Yasunori , Kusumoto Sojiro , Ishida Hiroo , Shirai Takao , Hirose Takashi , Ohnishi Tsukasa , Sasaki Yasutsuna
Published: April 2023

IGF1R-AKT activation via IRS1 signaling is required for the acquisition of EGFR and Met inhibitor resistance in DR2 cells.
Figure S1 from Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation
Authors: Yamaoka Toshimitsu , Ohmori Tohru , Ohba Motoi , Arata Satoru , Kishino Yasunari , Murata Yasunori , Kusumoto Sojiro , Ishida Hiroo , Shirai Takao , Hirose Takashi , Ohnishi Tsukasa , Sasaki Yasutsuna
Published: April 2023

Although both IGF1R and Insulin receptor (InsR) are activated, IGF1R but not InsR expression is required for regulating downstream signaling in DR2 and DR4 cells.
Supplementary Figure S4 from Interference with the HSF1/HSP70/BAG3 Pathway Primes Glioma Cells to Matrix Detachment and BH3 Mimetic–Induced Apoptosis
Authors: Antonietti Patrick , Linder Benedikt , Hehlgans Stephanie , Mildenberger Iris C. , Burger Michael C. , Fulda Simone , Steinbach Joachim P. , Gessler Florian , Rödel Franz , Mittelbronn Michel , Kögel Donat
Published: April 2023

KRIBB1 synergizes with the BH3 mimetic ABT-737.
Supplementary Data from Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody–Drug Conjugate Targeting 5T4
Authors: Harper Jay , Lloyd Christopher , Dimasi Nazzareno , Toader Dorin , Marwood Rose , Lewis Leeanne , Bannister David , Jovanovic Jelena , Fleming Ryan , D'Hooge Francois , Mao Shenlan , Marrero Allison M. , Korade Martin , Strout Patrick , Xu Linda , Chen Cui , Wetzel Leslie , Breen Shannon , van Vlerken-Ysla Lilian , Jalla Sanjoo , Rebelatto Marlon , Zhong Haihong , Hurt Elaine M. , Hinrichs Mary Jane , Huang Keven , Howard Philip W. , Tice David A. , Hollingsworth Robert E. , Herbst Ronald , Kamal Adeela
Published: April 2023

Supplementary Figure S1. Comparable internalization rates for 5T4_0108 and the 5T4-Tub ADC;Supplementary Figure S2. Affinity optimization improves in vitro cytotoxicity of a 5T4-ADC;Supplementary Figure S3. Induction of apoptosis by 5T4-PBD and 5T4-Tub;Supplementary Figure S4. 5T4 is expressed on CSCs of multiple cancer cell lines;Supplementary Figure S5. Only PBD is capable of inducing cytotoxicity of CSC populations in vitro;Supplementary Table S1. Improved cytotoxic potency following affinity optimization of 5T4 antibody; Supplementary Table S2. Quantification of cell surface-associated 5T4 in various cancer cell lines;Supplementary Table S3. Tumorigenicity of CSC populations derived from NCI- N87 and MDA-MB-361 xenografts; Supplementary Materials & Methods
Supplementary Information from Development and Application of a Novel Model System to Study “Active” and “Passive” Tumor Targeting
Authors: Mukherjee Amarnath , Kumar Binod , Hatano Koji , Russell Luisa M. , Trock Bruce J. , Searson Peter C. , Meeker Alan K. , Pomper Martin G. , Lupold Shawn E.
Published: April 2023

Table S1: Weight of the tumors;Figure S1: Correlation of in vivo NIR imaging and ex vivo biodistribution analysis; Figure S2: Evaluation of injected J591-conjugates; Figure S3: Assessment of tumor vascular permeability; Figure S4: Passive dye uptake in PSMA-positive and PSMA-negative tumors; Figure S5: Ex vivo tumor image analysis of LMD/PSMA xenograft model; Figure S6: Ex vivo biodistribution analysis of J591-conjugates in LMD tumor model; Figure S7: Ex vivo tumor image analysis of PC3/PSMA xenograft model; Figure S8: PSMA expression and J591 conjugate distribution
Supplemental Table 1 from Expression of GRP78, Master Regulator of the Unfolded Protein Response, Increases Chemoresistance in Pancreatic Ductal Adenocarcinoma
Authors: Gifford Jenifer B. , Huang Wei , Zeleniak Ann E. , Hindoyan Antreas , Wu Hong , Donahue Timothy R. , Hill Reginald
Published: April 2023

Patient Tumor Information
Supplemental Figure 2 from Expression of GRP78, Master Regulator of the Unfolded Protein Response, Increases Chemoresistance in Pancreatic Ductal Adenocarcinoma
Authors: Gifford Jenifer B. , Huang Wei , Zeleniak Ann E. , Hindoyan Antreas , Wu Hong , Donahue Timothy R. , Hill Reginald
Published: April 2023

Representative images of immunohistochemistry for P-AKT in PDX tumors.
Supplementary Figures 1-8 from An HRE-Binding Py-Im Polyamide Impairs Hypoxic Signaling in Tumors
Authors: Szablowski Jerzy O. , Raskatov Jevgenij A. , Dervan Peter B.
Published: April 2023

Supplementary Figure 1: Whole transcriptome analysis of U251 cells dosed with DFO and compounds 1 and 3; Supplementary Figure 2: Preliminary in vivo experiments - quantification of an uptake within of a radiolabeled Py-Im polyamide within tissues and subcellular localization of a fluorescently labeled compound; Supplementary Figure 3: Single-injection toxicity of a Py-Im polyamide 1; Supplementary Figure 4: Py-Im polyamide 1 attenuates tumor growth in GBM39 xenograftsu and explanation of dosing schedules and tumor growth curves for GBM39 tumors; Supplementary Figure 5: Mouse weight curves during treatment with Py-Im polyamide 1; Supplementary Figure 6: Measurements of vascular density for GBM39 tumors for two different dosing schedules; Supplementary Figure 7: In vivo Effects of treatment with 1 for GBM39 and U251 xenografts. Effects of treatment with 1 are consistent between GBM39 and U251 xenografts, and apoptosis results are consistent between TUNEL and CC3 staining. Supplementary Figure 8. Relation between HIF-1a accumulation and necrosis.
Supplementary Figure and table legends from An HRE-Binding Py-Im Polyamide Impairs Hypoxic Signaling in Tumors
Authors: Szablowski Jerzy O. , Raskatov Jevgenij A. , Dervan Peter B.
Published: April 2023

Legends for supplementary figures 1-8 and supplementary table 1-2.
Supplementary Figure S3 from Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 to Induce Apoptosis Specifically in p53-Defective Cancer Cells
Authors: Li Xinzhe , Li Bo , Ni Zhenhong , Zhou Peng , Wang Bin , He Jintao , Xiong Haojun , Yang Fan , Wu Yaran , Lyu Xilin , Zhang Yan , Zeng Yijun , Lian Jiqin , He Fengtian
Published: April 2023

Silencing or overexpressing the indicated genes in the presence of ABT-263 alone or the combination of metformin and ABT-263.
Supplementary Table S3 from Combinatorial Drug Screening Identifies Ewing Sarcoma–specific Sensitivities
Authors: Radic-Sarikas Branka , Tsafou Kalliopi P. , Emdal Kristina B. , Papamarkou Theodore , Huber Kilian V. M. , Mutz Cornelia , Toretsky Jeffrey A. , Bennett Keiryn L. , Olsen Jesper V. , Brunak Søren , Kovar Heinrich , Superti-Furga Giulio
Published: April 2023

Validation of PKC412 and BMS-754807 synergy in a panel of Ewing sarcoma cell lines. CI values are shown for each concentration point where the drugs were combined.
Supplementary Table S2 from Combinatorial Drug Screening Identifies Ewing Sarcoma–specific Sensitivities
Authors: Radic-Sarikas Branka , Tsafou Kalliopi P. , Emdal Kristina B. , Papamarkou Theodore , Huber Kilian V. M. , Mutz Cornelia , Toretsky Jeffrey A. , Bennett Keiryn L. , Olsen Jesper V. , Brunak Søren , Kovar Heinrich , Superti-Furga Giulio
Published: April 2023

Distribution of strong and very strong synergy across the three screens (appendix to Figure 1B and Figure 2A).
Supplementary Table S1 from Combinatorial Drug Screening Identifies Ewing Sarcoma–specific Sensitivities
Authors: Radic-Sarikas Branka , Tsafou Kalliopi P. , Emdal Kristina B. , Papamarkou Theodore , Huber Kilian V. M. , Mutz Cornelia , Toretsky Jeffrey A. , Bennett Keiryn L. , Olsen Jesper V. , Brunak Søren , Kovar Heinrich , Superti-Furga Giulio
Published: April 2023

Overview of compound libraries and sub-libraries used in the initial and parallel combinatorial screens.
Supplementary Figure S1 from Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 to Induce Apoptosis Specifically in p53-Defective Cancer Cells
Authors: Li Xinzhe , Li Bo , Ni Zhenhong , Zhou Peng , Wang Bin , He Jintao , Xiong Haojun , Yang Fan , Wu Yaran , Lyu Xilin , Zhang Yan , Zeng Yijun , Lian Jiqin , He Fengtian
Published: April 2023

The synergistic effect between metformin and ABT-263 is independent of the cell cycle changes and metformin sensitizes ABT-263 not via changing the levels of BCL-2, BCL-XL, cIAP1 and cIAP2.
Table S1 from Vessel-Targeted Chemophototherapy with Cationic Porphyrin-Phospholipid Liposomes
Authors: Luo Dandan , Geng Jumin , Li Nasi , Carter Kevin A. , Shao Shuai , Atilla-Gokcumen G. Ekin , Lovell Jonathan F.
Published: April 2023

Dox Pharmacokinetics of neutral Dox-PoP liposomes
Supplementary figure legends from MENA Confers Resistance to Paclitaxel in Triple-Negative Breast Cancer
Authors: Oudin Madeleine J. , Barbier Lucie , Schäfer Claudia , Kosciuk Tatsiana , Miller Miles A. , Han Sangyoon , Jonas Oliver , Lauffenburger Douglas A. , Gertler Frank B.
Published: April 2023

Figure legends for supplementary figures
Figure S6 from MENA Confers Resistance to Paclitaxel in Triple-Negative Breast Cancer
Authors: Oudin Madeleine J. , Barbier Lucie , Schäfer Claudia , Kosciuk Tatsiana , Miller Miles A. , Han Sangyoon , Jonas Oliver , Lauffenburger Douglas A. , Gertler Frank B.
Published: April 2023

Mena-driven resistance to paclitaxel does not involve Akt signaling
Figure S4 from Vessel-Targeted Chemophototherapy with Cationic Porphyrin-Phospholipid Liposomes
Authors: Luo Dandan , Geng Jumin , Li Nasi , Carter Kevin A. , Shao Shuai , Atilla-Gokcumen G. Ekin , Lovell Jonathan F.
Published: April 2023

Fluorescence images of Dox distribution at different time post i.v. injection of DOTAP liposomes or DOPC liposomes. Injection dose: 7 mg/kg liposomal Dox.
Figure S2 from Vessel-Targeted Chemophototherapy with Cationic Porphyrin-Phospholipid Liposomes
Authors: Luo Dandan , Geng Jumin , Li Nasi , Carter Kevin A. , Shao Shuai , Atilla-Gokcumen G. Ekin , Lovell Jonathan F.
Published: April 2023

Oxygen scavenger sodium sulfite inhibits light triggered drug release and prevent DOTAP oxidation upon laser. A) Dox release with oxygen scavenger sodium sulfite (25mM) and antioxidant sodium ascorbate (25 mM) Light triggered release was performed in PBS at room temperature. B) Relative ion counts of DOTAP +/- laser treatment and sodium sulfite (25 mM). Mean{plus minus}s.d. for n=3.
Figure S4 from MENA Confers Resistance to Paclitaxel in Triple-Negative Breast Cancer
Authors: Oudin Madeleine J. , Barbier Lucie , Schäfer Claudia , Kosciuk Tatsiana , Miller Miles A. , Han Sangyoon , Jonas Oliver , Lauffenburger Douglas A. , Gertler Frank B.
Published: April 2023

MENA isoform-driven taxane resistance affects progression through the cell cycle
Figure S3 from MENA Confers Resistance to Paclitaxel in Triple-Negative Breast Cancer
Authors: Oudin Madeleine J. , Barbier Lucie , Schäfer Claudia , Kosciuk Tatsiana , Miller Miles A. , Han Sangyoon , Jonas Oliver , Lauffenburger Douglas A. , Gertler Frank B.
Published: April 2023

MENA isoform driven taxane resistance is not due to drug efflux, FA signaling
Figure S2 from MENA Confers Resistance to Paclitaxel in Triple-Negative Breast Cancer
Authors: Oudin Madeleine J. , Barbier Lucie , Schäfer Claudia , Kosciuk Tatsiana , Miller Miles A. , Han Sangyoon , Jonas Oliver , Lauffenburger Douglas A. , Gertler Frank B.
Published: April 2023

Paclitaxel treatment decreases cell velocity in vitro
Figure S6 from Insulin-Mediated Signaling Facilitates Resistance to PDGFR Inhibition in Proneural hPDGFB-Driven Gliomas
Authors: Almiron Bonnin Damian A. , Ran Cong , Havrda Matthew C. , Liu Huan , Hitoshi Yasuyuki , Zhang Zhonghua , Cheng Chao , Ung Matthew , Israel Mark A.
Published: April 2023

PDGFR expression in recurring GFAP/tTA:TRE/hPDGFB allografts resistant to hPDGFB suppression.
Figure S4 from Insulin-Mediated Signaling Facilitates Resistance to PDGFR Inhibition in Proneural hPDGFB-Driven Gliomas
Authors: Almiron Bonnin Damian A. , Ran Cong , Havrda Matthew C. , Liu Huan , Hitoshi Yasuyuki , Zhang Zhonghua , Cheng Chao , Ung Matthew , Israel Mark A.
Published: April 2023

Increased IGF1R in recurring GFAP/tTA:TRE/hPDGFB allografts resistant to hPDGFB suppression.
Figure S3 from Insulin-Mediated Signaling Facilitates Resistance to PDGFR Inhibition in Proneural hPDGFB-Driven Gliomas
Authors: Almiron Bonnin Damian A. , Ran Cong , Havrda Matthew C. , Liu Huan , Hitoshi Yasuyuki , Zhang Zhonghua , Cheng Chao , Ung Matthew , Israel Mark A.
Published: April 2023

Relative cell growth of TSC-S1 cultures 96 hours after transfection with either PCDNA3 or PCDNA3-HA-myrAKT1 cultured in doxycycline or DMSO.
Figure S7 from Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma
Authors: Jain Salvia , Washington Abigail , Leaf Rebecca Karp , Bhargava Parul , Clark Rachael A. , Kupper Thomas S. , Stroopinsky Dina , Pyzer Athalia , Cole Leandra , Nahas Myrna , Apel Arie , Rosenblatt Jacalyn , Arnason Jon , Kufe Donald , Avigan David
Published: April 2023

Decitabine and GO-203 combination is synergistically cytotoxic in CTCL cells